Fresenius Medical Care stock: Parent cuts stake to 20%

Fresenius Medical Care stock traded at 40.14 euros on Lang & Schwarz at 17:40 CET on Friday, November 13, 2026, 0.10 percent above the Xetra close of Friday, November 13. The immediate company development is a completed share sale by parent Fresenius, announced on November 12.

Fresenius reduces its FMC holding

According to a Financial Times company announcement, Fresenius completed the sale of 13.4 million Fresenius Medical Care shares at 39.00 euros each. The transaction generated gross proceeds of approximately 524 million euros and reduced Fresenius's financial investment in FMC from approximately 25 percent to approximately 20 percent of issued share capital.

Settlement is expected on November 16, 2026. Fresenius said the net proceeds will support investment in its growth platforms and its strategic priorities. Its remaining FMC shares are subject to a 90-day lock-up, subject to customary exceptions.

Financial effect for the parent

Fresenius expects a book gain in the low to mid double-digit million euro range. The gain is expected to appear in Fresenius Group's fourth-quarter 2026 results as a special item; it is not an operating result of Fresenius Medical Care.

Bond settlement remains ahead

FMC also has a separate financing milestone ahead. The company placed a 500 million euro bond maturing in February 2032, with a 4.250 percent coupon, and plans settlement for November 16. The proceeds are intended for general corporate purposes, including refinancing existing financial liabilities.

German equities remain the broader setting for Fresenius Medical Care stock. Current market reports provide the wider market context.

More news and analyses on Fresenius Medical Care stock.